HOWL Company Profile and Key Details

HOWL has shown weak momentum, losing -1.78% over the past week and -64.72% over the past quarter, though year-to-date performance is down -10.91%. Short-term trend indicators are bullishly aligned (SMA20 -4.72%, SMA50 -5.57%, SMA200 -45.18%). The stock’s 14-day RSI is 44.44 (neutral), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.45% below its high and over 19.2% above its low. Average 10-day trading volume of 473.25 thousand shares is slightly above the 3-month average of 370.06 thousand, indicating heightened recent market interest.

Werewolf Therapeutics, Inc. has 45.73 million shares outstanding. The public float is 29.61 million shares, elevated short interest at 3.02% of float. This equals 982.02 thousand shares. The short ratio is 4.09 days. Institutional investors hold 52.3% of the float. Insiders own 5.96%. RA CAPITAL MANAGEMENT, L.P. holds 6.24 million shares, MPM BioVentures 2014, L.P. has 4.78 million shares and GADICKE ANSBERT has 4.78 million shares. Over the past six months, insider transactions show net selling. They sold 4.99 million shares across 99 transactions.

Werewolf Therapeutics, Inc. generated EPS of -$1.62 over the past year. Five-year average earnings growth is -20.76%. Wall Street analysts project EPS growth of -2.89% annually over the next five years. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$11.33. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $3.00. The high target offers 1349.28% upside. The low target suggests 334.78% downside. The mean target is $7.00. This offers 914.49% upside. Werewolf Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended March 27, 2026, missed forecasts by -41.18%. The prior quarter beat by -8.36%. Over the last six quarters, Apple has recorded several small beats. These include -7.32% in November 07, 2024.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) closed at $0.69 USD, losing -$0.03 (-4.56%) from the previous close of $0.72. The stock is currently mid-range between its 52-week high and low $0.53 and $2.38. With a market capitalization of about $33.53 million, Werewolf Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.41). Key stats such as the average daily volume over the past year has been around 384.38 thousand shares, volume is running light vs its 52-week average. Headquartered in Watertown, MA, Werewolf Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel J. Hicklin, the company employs approximately 46 people and listed since April 30, 2021. Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Werewolf Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.04. This means the shares are trading below this model’s fair value.

Werewolf Therapeutics, Inc. trades at a P/E ratio of -0.54, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.33 suggesting the stock is closer to book value. The P/FCF stands at -0.58, also below market averages.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shares are down -10.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Werewolf Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.20, suggesting 1668.12% upside. Our AI forecast model points to short-term strength (1.45% over two weeks), a medium-term fall (-73.91% over three months), and a longer-term loss (-26.09% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Werewolf Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.45%, with price expected at $0.70 by May 18, 2026, within a range of $0.59 to $0.80 3-Month Outlook: Projected fall of -73.91%, reaching $0.18 by July 31, 2026, with a range of $0.08 to $0.23. 1-Year Outlook: Projected loss of -26.09%, with price at $0.51 by May 04, 2027, within a range of $0.00 to $0.00.